Mobile

A study evaluating the safety and efficacy of the combination of GS-4059 and Entospletinib with and without obinutuzumab in subjects with chronic lymphocytic leukemia

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002768-15

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the preliminary efficacy of finite therapy with the combination of GS-4059 and entospletinib with and without obinutuzumab in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL)

Critère d'inclusion

  • Adults with relapsed or refractory chronic lymphocytic leukemia

Liens